These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26259025)

  • 1. The impact of the concentration of drug binding plasma proteins on drug distribution according to Øie-Tozer's model.
    Svennebring AM
    Xenobiotica; 2016; 46(4):307-14. PubMed ID: 26259025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The usefulness of Øie-Tozer's model in deriving pharmacokinetic changes in response to changes in the concentration of drug-binding plasma protein.
    Svennebring A
    Xenobiotica; 2016 Jul; 46(7):659-663. PubMed ID: 30179078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visualization of plasma and tissue binding using dose fractions parameter.
    Svennebring A
    Drug Dev Res; 2014 Nov; 75(7):425-37. PubMed ID: 25315512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
    Sui X; Sun J; Li H; Wang Y; Liu J; Liu X; Zhang W; Chen L; He Z
    Eur J Med Chem; 2009 Nov; 44(11):4455-60. PubMed ID: 19586686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Distribution Part 2. Predicting Volume of Distribution from Plasma Protein Binding and Membrane Partitioning.
    Korzekwa K; Nagar S
    Pharm Res; 2017 Mar; 34(3):544-551. PubMed ID: 27966088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating unbound volume of distribution and tissue binding by in vitro HPLC-based human serum albumin and immobilised artificial membrane-binding measurements.
    Valkó KL; Nunhuck SB; Hill AP
    J Pharm Sci; 2011 Mar; 100(3):849-62. PubMed ID: 20891009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the Øie-Tozer model in understanding mechanisms and determinants of drug distribution.
    Waters NJ; Lombardo F
    Drug Metab Dispos; 2010 Jul; 38(7):1159-65. PubMed ID: 20375179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma and tissue binding considerations in drug disposition.
    Wilkinson GR
    Drug Metab Rev; 1983; 14(3):427-65. PubMed ID: 6347593
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of unbound volumes of drug distribution in pharmacokinetic calculations.
    Stepensky D
    Eur J Pharm Sci; 2011 Jan; 42(1-2):91-8. PubMed ID: 21050885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drug binding to blood proteins: characteristics, roles and pathophysiological changes].
    Tillement JP; Duché JC; Barré J
    Bull Acad Natl Med; 2006; 190(4-5):935-46; discussion 946-7. PubMed ID: 17195618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of plasma protein and tissue binding on the time course of drug concentration in plasma.
    McNamara PJ; Levy G; Gibaldi M
    J Pharmacokinet Biopharm; 1979 Apr; 7(2):195-206. PubMed ID: 20218014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug binding to plasma proteins.
    Paxton JW
    N Z Med J; 1985 Apr; 98(776):245-8. PubMed ID: 3857503
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug distribution and binding.
    Oie S
    J Clin Pharmacol; 1986; 26(8):583-6. PubMed ID: 3793947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
    Lombardo F; Obach RS; Shalaeva MY; Gao F
    J Med Chem; 2004 Feb; 47(5):1242-50. PubMed ID: 14971904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma protein binding and distribution characteristics of drugs as indices of their hemodialyzability.
    Gwilt PR; Perrier D
    Clin Pharmacol Ther; 1978 Aug; 24(2):154-61. PubMed ID: 679594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apparent volumes of distribution and drug binding to plasma proteins and tissues.
    Gibaldi M; McNamara PJ
    Eur J Clin Pharmacol; 1978 Jul; 13(5):373-80. PubMed ID: 668796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A paradigm shift in pharmacokinetic-pharmacodynamic (PKPD) modeling: rule of thumb for estimating free drug level in tissue compared with plasma to guide drug design.
    Poulin P
    J Pharm Sci; 2015 Jul; 104(7):2359-68. PubMed ID: 25943586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for monitoring free drug levels.
    Levy RH; Moreland TA
    Clin Pharmacokinet; 1984 Jan; 9 Suppl 1():1-9. PubMed ID: 6705421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding and displacement of basic, acidic and neutral drugs in normal and orosomucoid-deficient plasma.
    Pike E; Skuterud B; Kierulf P; Fremstad D; Abdel Sayed SM; Lunde PK
    Clin Pharmacokinet; 1981; 6(5):367-74. PubMed ID: 7333058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease.
    Keller F; Maiga M; Neumayer HH; Lode H; Distler A
    Eur J Drug Metab Pharmacokinet; 1984; 9(3):275-82. PubMed ID: 6519129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.